VasoMedical Successfully Exhibited at the 61st Annual Scientific Sessions of the American College of Cardiology
April 3, 2012 - WESTBURY, NY - VasoMedical, Inc. (“VasoMedical”) (OTC: VASO.PK), a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products, today announced that its participation at the 61st Annual Scientific Sessions of the American College of Cardiology (“ACC”), which concluded last week in Chicago, IL., drew high levels of interest.
For the past 17 years in a row, VasoMedical has exhibited and conducted live demonstrations of its proprietary Enhanced External Counterpulsation (EECP®) therapy at the annual Scientific Sessions of the ACC. The well received display this year significantly enhanced the presence of VasoMedical in the cardiology world with its exhibit, an attractive, large island booth with its tower emblazoned with the VasoMedical logo and brands visible throughout much of the exhibition hall. Visitors were also impressed by the graphic display proudly showing the flags of 69 countries in which VasoMedical has entered the market and is actively promoting both its EECP® systems, its state-of-the-art BIOXTM ECG Holter and Ambulatory Blood Pressure monitoring systems and its patient management products.
“The interest shown in our product line by physicians attending the conference, as well as in VasoMedical's new corporate image as a group of medtech companies focusing on delivering quality healthcare products, was extremely rewarding,” said Dr. Jun Ma, President and CEO. “As our effort in promoting clinical benefits of EECP® therapy to practicing physicians is continued, we are also actively demonstrating to the healthcare community the cost effectiveness of EECP® therapy by reducing emergency room visits and hospitalization of cardiac patients. This is a very important message, especially in these uncertain times in healthcare,” he continued.
As part of it global marketing plan, VasoMedical is scheduled to participate and exhibit at many future international meetings, including the following for the rest of 2012:
- April 17-20, 2012: China Medical Equipment Fair (CMEF), the largest medical equipment show in Asia, in Shenzhen, Guangdong, China;
- April 18-22, 2012: World Congress of Cardiology (WCC) meeting in Dubai, United Arab Emirates;
- May 22-25, 2012: Hospitalar meeting in Sao Paulo, Brazil;
- August 25-29, 2012: European Society of Cardiology (ESC) meeting in Munich, Germany;
- November 3-7, 2012: American Heart Association (AHA) meeting in Los Angeles, CA;
- November 14-17, 2012: Medica, the largest medical equipment show in the world, in Dusseldorf, Germany;
- December 5-8, 2012: and the Russian Pharma and Medical Device meeting in Moscow, Russia.
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through three wholly-owned subsidiaries. VasoMedical Solutions manages and coordinates the design, manufacture and sales of EECP® therapy systems, its core product, as well as other medical equipment operations; VasoMedical Global operates the Company’s China-based subsidiaries; and Vaso Diagnostics, d/b/a VasoHealthcare, is the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products. Additional information is available on the Company's website at www.vasomedical.com.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.